Global Study Associate Director Haematology

Join us in leading global clinical studies that have the power to improve patients’ lives.

At Acerta Pharma, a member of the AstraZeneca Group, you will help deliver meaningful studies in haematology while working with international teams in a role with real visibility and impact.

Global Study Associate Director

Haematology Clinical Operations | Fulltime

Oss | Amsterdam

Hybrid working model

Acerta Pharma will be relocating to Amsterdam, where are building our Oncology Research & Development Hub, with the current move planned for early 2027. Until that time, the working arrangement will be as follows: employees will work 1 day per week from the Oss location, 2 days per week from the Amsterdam office, and the remaining days from home. This schedule results in an overall office presence of 60%.

Are you ready to help drive global clinical studies that can make a real difference to patients' lives?

At Acerta Pharma, part of the AstraZeneca Group, we are committed to improving treatment options for patients with haematological malignancies. As our portfolio continues to grow from early development through registration and beyond, we are looking for an experienced and proactive Global Study Associate Director to join our Clinical Operations team.

In this role, you will help lead the operational delivery of global haematology studies and work closely with colleagues across functions, countries, and development stages. This is a visible role with real impact, offering strong opportunities for growth and development within an international environment.

The role

As Global Study Associate Director, you will be responsible for the end-to-end operational planning and delivery of complex global clinical studies. You will play an important role in shaping how studies are delivered - not only by keeping them on track, but also by helping define the operational approach, bringing teams together, and driving high standards across study execution. This role is not limited to one development phase. We welcome candidates with experience across different stages of clinical development, from early phase through to late phase and registration studies.

You will work closely with Senior Global Program Directors and be part of a collaborative global team with colleagues across multiple countries. In our haematology Clinical Operations department, we highly invest in our people to grow and develop towards a more senior global project leadership path.

Your impact

In this role, you will:

• Lead and support a cross-functional global study team.

• Drive the operational strategy for your studies, not just the day-to-day execution.

• Ensure studies are delivered on time, within budget, and in line with quality and regulatory standards.

• Act as a key operational partner to senior program and clinical team stakeholders.

• Contribute to program-level initiatives and continuous improvement projects.

• Build strong working relationships across teams, functions, and regions.

• Help create a collaborative way of working that supports both quality delivery and team effectiveness.

What you bring

We are looking for someone who combines clinical operations experience with a practical, collaborative approach.

You will likely bring:

• Minimum of 5 years of progressive experience in clinical research, with at least 3 years of clinical development project management experience.

• Experience within the pharmaceutical and/or with CRO is a must (oncology /haematology experience is a bonus).

• Experience managing or contributing to complex international studies in a structured and proactive way.

• The ability to balance strategy and delivery.

• Confidence working with colleagues and stakeholders across countries and functions.

• Strong organisational skills and the ability to manage priorities in a changing environment.

• A leadership style that is clear, supportive, and team focused.

• Fluent English, both written and spoken.

• You are currently living in the Netherlands and hold an EU passport.

Why join Acerta Pharma

This is an opportunity to join a company working at the forefront of innovation in haematology and to contribute to studies that matter to patients worldwide. You will be part of an international and collaborative team, with the chance to grow your experience, broaden your exposure, and help shape the delivery of important global clinical programs.

Hybrid working model

Until we move to Amsterdam, currently scheduled for early 2027 (60% office based):

•    1-2 days per week in Oss

•    1-2 days per week in Amsterdam

•    Remaining days remote

After office relocation:

•    60% office based in our new Amsterdam office

•    40% remote

What we offer

A dynamic, innovative, and international working environment. You are part of the development process of new drugs that can make a difference in the lives of blood cancer patients and their loved ones. In addition:

•    The opportunity to further develop yourself, for example, into a position offering even more responsibility. International growth (within AstraZeneca) is also one of the possibilities.

•    Good primary & secondary benefits including 8% holiday allowance, 27 holidays on a full-time basis plus office closure between Christmas and New Year + Good Friday. 

•    Collective pension with a fixed percentage personal contribution.

•    Bonus scheme. 

•    Personal budget which can be used for vitality, home office equipment, sustainability or personal development. 

•    Access to internal training and learning and development offerings. 

About AstraZeneca Oncology R&D, Amsterdam

At AstraZeneca Amsterdam, we bring together two research groups, in haemato-oncology and next-generation cell therapy research. Together, they form our Oncology R&D hub in the Netherlands, working closely with colleagues in the US, Canada, Spain and the UK, to develop innovative treatments for patients with cancer.

Our hematology R&D group was born as Acerta Pharma, one of the Netherlands’ greatest biotech success stories. Its small-molecule BTK inhibitor has been approved by both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of Chronic Lymphocytic Leukaemia (CLL) and Mantle Cell Lymphoma (MCL). In Amsterdam approximately 100 colleagues continue the development of new therapies for haematological malignancies under the AstraZeneca brand name.

AstraZeneca’s Cell Therapy R&D team focuses on developing next-generation T-cell receptor (TCR) therapies targeting neoantigens in solid tumours. With a team of around 75 scientists, we work on both fully individualised and shared neo-antigen approaches, with the aim of improving outcomes for patients with cancer.

Our oncology research and development hub is anchored by our new state-of-the-art laboratories in OneHelix and the adjacent Plus Ultra Amsterdam building, both located on the Amsterdam University Medical Centre (Amsterdam UMC) campus. Our hub is firmly positioned at the heart of the Dutch research community, creating new opportunities for our people and science as we work to transform the lives of patients.

Apply:

If you have any questions about this vacancy, our Recruitment Team, Karin Raadschelders / Caroline van Oppen are happy to inform you.  info@werkenbijacertapharma.nl or by phone on +31(0)85 - 047 0244.

We do not have a fixed closing date; the vacancy will close as soon as we find the right candidate. Please apply immediately, as we will begin the selection process right away.

Date Posted

Closing Date

AstraZeneca embraces diversity and equality of opportunity.  We are committed to building an inclusive and diverse team representing all backgrounds, with as wide a range of perspectives as possible, and harnessing industry-leading skills.  We believe that the more inclusive we are, the better our work will be.  We welcome and consider applications to join our team from all qualified candidates, regardless of their characteristics.  We comply with all applicable laws and regulations on non-discrimination in employment (and recruitment), as well as work authorization and employment eligibility verification requirements.